- Investing.com
TCM Limited engages in the generation of power using solar energy worldwide. The company operates through Trading, Manufacturing, Educational, and Real Estate segments. It trades and installs solar panels, auto care, and health care related products. The company also provides diagnostic equipment and reagents; and manufactures organic and inorganic chemicals, fungicides, herbicides, barium and strontium salts, strontium nitrite, sodium sulfide and various other derivatives. In addition, it manufactures cattle feed; and offers online education solutions. Further, the company is involved in the development and sale of real estate; aquaculture business; and trades in fuel oil, food stuff, pulses and grains, fertilizer, farm products, meat and poultry, fish and fishery products, minerals, etc. The company was formerly known as Travancore Chemical Manufacturing Company Ltd. and changed its name to TCM Limited in 1996. TCM Limited was incorporated in 1943 and is based in Cochin, India.
CNS Drug Pipeline | Explore Trevena's innovative treatments for neuropathic pain and epilepsy, with TRV-045 as the primary value driver showing promising results in proof-of-concept studies |
Financial Challenges | Delve into Trevena's financial health, marked by a weak overall score, high price volatility, and strategic moves to bolster its cash position and reduce liabilities |
Market Positioning | Learn how Trevena navigates the competitive CNS disorder treatment landscape, balancing its small-cap status against potential breakthroughs in high-value markets |
Future Prospects | Analyst price target of $3.00, with potential catalysts including TRV-045 updates and strategic decisions on OLINVYK that could reshape Trevena's market position |
Metrics to compare | TRVN | Sector Sector - Average of metrics from a broad group of related Basic Materials sector companies | Relationship RelationshipTRVNPeersSector | |
---|---|---|---|---|
P/E Ratio | 18.1x | 23.3x | 2.2x | |
PEG Ratio | 0.10 | 0.21 | 0.00 | |
Price/Book | 1.0x | 2.3x | 1.6x | |
Price / LTM Sales | 1.1x | 1.8x | 1.3x | |
Upside (Analyst Target) | - | 14.2% | 20.9% | |
Fair Value Upside | Unlock | −1.4% | 1.2% | Unlock |